iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith

Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases. Two recent first-of-its-kind clinical case reports on the iPSC-based treatment of age-related macular degeneration (AMD) highlight the hopes and challenges associated with the clinical application of iPSCs...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fei, Hu, Jim, He, Tong-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136587/
https://www.ncbi.nlm.nih.gov/pubmed/30258908
http://dx.doi.org/10.1016/j.gendis.2017.03.001
_version_ 1783355030394372096
author Li, Fei
Hu, Jim
He, Tong-Chuan
author_facet Li, Fei
Hu, Jim
He, Tong-Chuan
author_sort Li, Fei
collection PubMed
description Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases. Two recent first-of-its-kind clinical case reports on the iPSC-based treatment of age-related macular degeneration (AMD) highlight the hopes and challenges associated with the clinical application of iPSCs.
format Online
Article
Text
id pubmed-6136587
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-61365872018-09-26 iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith Li, Fei Hu, Jim He, Tong-Chuan Genes Dis Article Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases. Two recent first-of-its-kind clinical case reports on the iPSC-based treatment of age-related macular degeneration (AMD) highlight the hopes and challenges associated with the clinical application of iPSCs. Chongqing Medical University 2017-04-01 /pmc/articles/PMC6136587/ /pubmed/30258908 http://dx.doi.org/10.1016/j.gendis.2017.03.001 Text en Copyright © 2017, Chongqing Medical University. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Li, Fei
Hu, Jim
He, Tong-Chuan
iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title_full iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title_fullStr iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title_full_unstemmed iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title_short iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith
title_sort ipsc-based treatment of age-related macular degeneration (amd): the path to success requires more than blind faith
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136587/
https://www.ncbi.nlm.nih.gov/pubmed/30258908
http://dx.doi.org/10.1016/j.gendis.2017.03.001
work_keys_str_mv AT lifei ipscbasedtreatmentofagerelatedmaculardegenerationamdthepathtosuccessrequiresmorethanblindfaith
AT hujim ipscbasedtreatmentofagerelatedmaculardegenerationamdthepathtosuccessrequiresmorethanblindfaith
AT hetongchuan ipscbasedtreatmentofagerelatedmaculardegenerationamdthepathtosuccessrequiresmorethanblindfaith

Ejemplares similares